Special Use - Results Surveillance on Long-term Use With Wegovy®

Sponsor
Novo Nordisk A/S
Study ID
NCT06283667
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.

Study Details

The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor. The study will last for about 4 years. Participant will be in the study for about 2 years (104 weeks).

Key Dates

Start date
Jun 11, 2024
Status verified
Apr 2026
Primary completion
Jan 31, 2028
Completion
Jan 31, 2028

Study Design

Enrollment
1,071 participants (actual)

Arms

  • Arm: Wegovy®
    Patients with obesity treated with Wegovy® (semaglutide) once weekly under real-world clinical practice conditions in Japan.

Primary Outcome Measure

Number of Adverse Reactions (ARs) [ Time Frame: From baseline (week 0) to end of study (week 104) ]

Related Studies